A court ruling doesn’t permit schools to “force-vaccinate” students, it addresses civil liability for accidentally ...
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...
Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
LOS ANGELES, Dec. 13 (Xinhua) -- An injectable HIV drug with novel mechanism was named on Thursday by the influential U.S. journal "Science" as Breakthrough of the Year. The drug, named lenacapavir, ...